Trial Profile

Phase I Study to Evaluate the Safety ,Tolerability, and Pharmacokinetics of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HRS 4642 (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

09 Nov 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
24 Oct 2023 Preliminary (n=18, At data cutoff on Aug 4, 2023) results of the dose escalation part assessing safety and efficacy of HRS-4642 in patients with advanced KRAS G12D mutant solid tumors, presented at the 48th European Society for Medical Oncology Congress.
21 Oct 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com